King's College London

Research portal

Parkinson’s disease, diabetes and cognitive impairment

Research output: Contribution to journalReview articlepeer-review

Mohamed Ashraghi, Gennaro Pagano, Sotirios Polychronis , Flavia Niccolini, Marios Politis

Original languageEnglish
Pages (from-to)11-21
Number of pages11
JournalRecent patents on endocrine, metabolic & immune drug discovery
Volume10
Issue number1
DOIs
Accepted/In press16 Jun 2016
Published2016

Documents

King's Authors

Abstract

BACKGROUND:
Parkinson's disease is a chronic neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons. The pathophysiological mechanisms underlying Parkinson's are still unknown. Mitochondrial dysfunction, abnormal protein aggregation, increased neuroinflammation and impairment of brain glucose metabolism are shared processes among insulin-resistance, diabetes and neurodegeneration and have been suggested as key mechanisms in development of Parkinson's and cognitive impairment.

OBJECTIVE:
To review experimental and clinical evidence of underlying Parkinson's pathophysiology in common with diabetes and cognitive impairment. Anti-diabetic agents and recent patents for insulin-resistance that might be repositioned in the treatment of Parkinson's also have been included in this review.
METHOD:
A narrative review using MEDLINE database.
RESULTS:
Common antidiabetic treatments such as DPP4 inhibitors, GLP-1 agonists and metformin have shown prom-ise in the treatment of Parkinson's disease and cognitive impairment in animals and humans. Study of the pathophysiology of neurodegeneration common between diabetes and Parkinson's disease has given rise to new treatment possibilities. Patents published in the last 5 years could be used in novel approaches to Parkinson's treatment by targeting specific pathophysiology proteins, such as Nurr1, PINK1 and NrF2, while patents to improve penetration of the blood brain barrier could allow improved efficacy of existing treatments.
CONCLUSION:
Further studies using GLP-1 agonists and DPP-4 inhibitors to treat PD are warranted as they have shown promise.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454